{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T07:21:14Z","timestamp":1781421674234,"version":"3.54.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1007\/s11920-005-0078-4","type":"journal-article","created":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T13:00:48Z","timestamp":1180789248000},"page":"252-257","source":"Crossref","is-referenced-by-count":22,"title":["Predictors of pharmacotherapy response in anxiety disorders"],"prefix":"10.1007","volume":"7","author":[{"given":"Damiaan","family":"Denys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"de Geus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"78_CR1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145704004675","volume":"8","author":"NA Fineberg","year":"2005","unstructured":"Fineberg NA, Gale TM: Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 2005, 8:107\u2013129. This is an excellent review on pharmacotherapy in OCD with critical notes and useful clinical comments.","journal-title":"Int J Neuropsychopharmacol"},{"key":"78_CR2","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, et al.: The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989, 46:1006\u20131011.","journal-title":"Arch Gen Psychiatry"},{"key":"78_CR3","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/archpsyc.1989.01810110054008","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, et al.: The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989, 46:1012\u20131016.","journal-title":"Arch Gen Psychiatry"},{"key":"78_CR4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00004850-200311000-00002","volume":"18","author":"D Denys","year":"2003","unstructured":"Denys D, Burger H, van Megen H, et al.: A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2003, 18:315\u2013322. The authors propose a prediction rule on the joint predictive value of different clinical variables and include an exhaustive overview of response prediction studies in OCD.","journal-title":"Int Clin Psychopharmacol"},{"key":"78_CR5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1176\/appi.ajp.162.2.228","volume":"162","author":"D Mataix-Cols","year":"2005","unstructured":"Mataix-Cols D, Rosario-Campos MC, Leckman JF: A multidimensional model of obsessive-compulsive disorder. Am J Psychiatry 2005, 162:228\u2013238.","journal-title":"Am J Psychiatry"},{"key":"78_CR6","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1176\/ajp.156.9.1409","volume":"156","author":"D Mataix-Cols","year":"1999","unstructured":"Mataix-Cols D, Rauch SL, Manzo PA, et al.: The use of factoranalyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry 1999, 156:1409\u20131416.","journal-title":"Am J Psychiatry"},{"key":"78_CR7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.psychres.2003.10.001","volume":"125","author":"F Neziroglu","year":"2004","unstructured":"Neziroglu F, Pinto A, Yaryura-Tobias JA, et al.: Overvalued ideation as a predictor of fluvoxamine response in patients with obsessive-compulsive disorder. Psychiatry Res 2004, 125:53\u201360.","journal-title":"Psychiatry Res"},{"key":"78_CR8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eurpsy.2003.12.005","volume":"19","author":"K,V Ravi","year":"2004","unstructured":"Ravi K,V, Samar R, Janardhan Reddy YC, et al.: Clinical characteristics and treatment response in poor and good insight obsessive-compulsive disorder. Eur Psychiatry 2004, 19:202\u2013208.","journal-title":"Eur Psychiatry"},{"key":"78_CR9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.jcp.0000104905.75206.50","volume":"24","author":"R Delorme","year":"2004","unstructured":"Delorme R, Chabane N, Callebert J, et al.: Platelet serotonergic predictors of clinical improvement in obsessive compulsive disorder. J Clin Psychopharmacol 2004, 24:18\u201323.","journal-title":"J Clin Psychopharmacol"},{"key":"78_CR10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00023210-200418050-00004","volume":"18","author":"SR Bareggi","year":"2004","unstructured":"Bareggi SR, Bianchi L, Cavallaro R, et al.: Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. CNS Drugs 2004, 18:329\u2013335.","journal-title":"CNS Drugs"},{"key":"78_CR11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1176\/appi.neuropsych.14.3.249","volume":"14","author":"RA Hurley","year":"2002","unstructured":"Hurley RA, Saxena S, Rauch SL, et al.: Predicting treatment response in obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 2002, 14:249\u2013253. This is a short but thorough overview on response prediction in OCD, including mainly neuro-imaging studies.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"78_CR12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/155005940303400205","volume":"34","author":"ES Hansen","year":"2003","unstructured":"Hansen ES, Prichep LS, Bolwig TG, et al.: Quantitative electroencephalography in OCD patients treated with paroxetine. Clin Electroencephalogr 2003, 34:70\u201374.","journal-title":"Clin Electroencephalogr"},{"key":"78_CR13","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0893-133X(02)00351-2","volume":"27","author":"SL Rauch","year":"2002","unstructured":"Rauch SL, Shin LM, Dougherty DD, et al.: Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 2002, 27:782\u2013791.","journal-title":"Neuropsychopharmacology"},{"key":"78_CR14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1176\/appi.ajp.160.3.522","volume":"160","author":"S Saxena","year":"2003","unstructured":"Saxena S, Brody AL, Ho ML, et al.: Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry 2003, 160:522\u2013532.","journal-title":"Am J Psychiatry"},{"key":"78_CR15","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/00004583-200009000-00008","volume":"39","author":"DR Rosenberg","year":"2000","unstructured":"Rosenberg DR, MacMaster FP, Keshavan MS, et al.: Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000, 39:1096\u20131103.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"78_CR16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-244X-4-30","volume":"4","author":"PD Carey","year":"2004","unstructured":"Carey PD, Warwick J, Niehaus DJH, et al.: Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BMC Psychiatry 2004, 4:30.","journal-title":"BMC Psychiatry"},{"key":"78_CR17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0925-4927(03)00091-X","volume":"124","author":"T Hendler","year":"2003","unstructured":"Hendler T, Goshen E, Tzila ZS, et al.: Brain reactivity to specific symptom provocation indicates prospective therapeutic outcome in OCD. Psychiatry Res 2003, 124:87\u2013103.","journal-title":"Psychiatry Res"},{"key":"78_CR18","doi-asserted-by":"crossref","unstructured":"Castillo AR, Buchpiguel CA, de Araujo LA, et al.: Brain SPECT imaging in children and adolescents with obsessivecompulsive disorder. J Neural Transm 2005, In press.","DOI":"10.1007\/s00702-004-0240-x"},{"key":"78_CR19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3349\/ymj.2004.45.1.90","volume":"45","author":"RS Diler","year":"2004","unstructured":"Diler RS, Kibar M, Avci A: Pharmacotherapy and regional cerebral blood flow in children with obsessive compulsive disorder. Yonsei Med J 2004, 45:90\u201399.","journal-title":"Yonsei Med J"},{"key":"78_CR20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/sj.npp.1300399","volume":"29","author":"PR Szeszko","year":"2004","unstructured":"Szeszko PR, MacMillan S, McMeniman M, et al.: Amygdala volume reductions in pediatric patients with obsessivecompulsive disorder treated with paroxetine: preliminary findings. Neuropsychopharmacology 2004, 29:826\u2013832.","journal-title":"Neuropsychopharmacology"},{"key":"78_CR21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.mp.4000391","volume":"3","author":"CJ McDougle","year":"1998","unstructured":"McDougle CJ, Epperson CN, Price LH, et al.: Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry 1998, 3:270\u2013273.","journal-title":"Mol Psychiatry"},{"key":"78_CR22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.mp.4000257","volume":"2","author":"EA Billett","year":"1997","unstructured":"Billett EA, Richter MA, King N, et al.: Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene. Mol Psychiatry 1997, 2:403\u2013406.","journal-title":"Mol Psychiatry"},{"key":"78_CR23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.mp.4000689","volume":"5","author":"DD Bella Di","year":"2000","unstructured":"Di Bella DD, Catalano M, Cavallini MC, et al.: Serotonin transporter linked polymorphic region in anorexia nervosa and bulimia nervosa. Mol Psychiatry 2000, 5:233\u2013234.","journal-title":"Mol Psychiatry"},{"key":"78_CR24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jad.2004.03.011","volume":"82","author":"J Sareen","year":"2004","unstructured":"Sareen J, Kirshner A, Lander M, et al.: Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review. J Affect Disord 2004, 82:167\u2013174.","journal-title":"J Affect Disord"},{"key":"78_CR25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1017\/S1092852900022392","volume":"9","author":"M Ameringen Van","year":"2004","unstructured":"Van Ameringen M, Mancini C, Pipe B, et al.: Optimizing treatment in social phobia: a review of treatment resistance. CNS Spectr 2004, 9:753\u2013762.","journal-title":"CNS Spectr"},{"key":"78_CR26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-198808000-00008","volume":"8","author":"M Versiani","year":"1988","unstructured":"Versiani M, Mundim FD, Nardi AE, et al.: Tranylcypromine in social phobia. J Clin Psychopharmacol 1988, 8:279\u2013283.","journal-title":"J Clin Psychopharmacol"},{"key":"78_CR27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00004850-199709000-00001","volume":"12","author":"M Versiani","year":"1997","unstructured":"Versiani M, Amrein R, Montgomery SA: Social phobia: long-term treatment outcome and prediction of response\u2014a moclobemide study. Int Clin Psychopharmacol 1997, 12:239\u2013254.","journal-title":"Int Clin Psychopharmacol"},{"key":"78_CR28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004714-199908000-00010","volume":"19","author":"AC Pande","year":"1999","unstructured":"Pande AC, Davidson JR, Jefferson JW, et al.: Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999, 19:341\u2013348.","journal-title":"J Clin Psychopharmacol"},{"key":"78_CR29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0887-6185(00)00027-X","volume":"14","author":"MW Otto","year":"2000","unstructured":"Otto MW, Pollack MH, Gould RA, et al.: A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord 2000, 14:345\u2013358.","journal-title":"J Anxiety Disord"},{"key":"78_CR30","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/00005053-199612000-00003","volume":"184","author":"SM Sutherland","year":"1996","unstructured":"Sutherland SM, Tupler LA, Colket JT, et al.: A 2-year follow-up of social phobia. Status after a brief medication trial. J Nerv Ment Dis 1996, 184:731\u2013738.","journal-title":"J Nerv Ment Dis"},{"key":"78_CR31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0165-0327(96)00013-4","volume":"39","author":"BR Slaap","year":"1996","unstructured":"Slaap BR, van Vliet IM, Westenberg HG, et al.: Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response. J Affect Disord 1996, 39:13\u201319.","journal-title":"J Affect Disord"},{"issue":"Suppl 1","key":"78_CR32","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0165-0327(98)00093-7","volume":"50","author":"SA Montgomery","year":"1998","unstructured":"Montgomery SA: Implications of the severity of social phobia. J Affect Disord 1998, 50(Suppl 1):S17-S22.","journal-title":"J Affect Disord"},{"key":"78_CR33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s002130100880","volume":"158","author":"DJ Stein","year":"2001","unstructured":"Stein DJ, Stein MB, Goodwin W, et al.: The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder. Psychopharmacology (Berl) 2001, 158:267\u2013272.","journal-title":"Psychopharmacology (Berl)"},{"key":"78_CR34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4088\/JCP.v63n0211","volume":"63","author":"DJ Stein","year":"2002","unstructured":"Stein DJ, Stein MB, Pitts CD, et al.: Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 2002, 63:152\u2013155.","journal-title":"J Clin Psychiatry"},{"key":"78_CR35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01.jcp.0000104909.75206.6f","volume":"24","author":"M Ameringen Van","year":"2004","unstructured":"Van Ameringen M, Oakman J, Mancini C, et al.: Predictors of response in generalized social phobia: effect of age of onset. J Clin Psychopharmacol 2004, 24:42\u201348.","journal-title":"J Clin Psychopharmacol"},{"key":"78_CR36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00005053-200201000-00010","volume":"190","author":"DB Oosterbaan","year":"2002","unstructured":"Oosterbaan DB, van Balkom AJ, Spinhoven P, et al.: The influence on treatment gain of comorbid avoidant personality disorder in patients with social phobia. J Nerv Ment Dis 2002, 190:41\u201343.","journal-title":"J Nerv Ment Dis"},{"key":"78_CR37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0278-5846(99)00109-8","volume":"24","author":"G Linden Van der","year":"2000","unstructured":"Van der Linden G, van Heerden B, Warwick J, et al.: Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog Neuropsychopharmacol Biol Psychiatry 2000, 24:419\u2013438.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"78_CR38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archpsyc.59.5.425","volume":"59","author":"T Furmark","year":"2002","unstructured":"Furmark T, Tillfors M, Marteinsdottir I, et al.: Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry 2002, 59:425\u2013433.","journal-title":"Arch Gen Psychiatry"},{"key":"78_CR39","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1176\/appi.ajp.158.12.1989","volume":"158","author":"MW Otto","year":"2001","unstructured":"Otto MW, Tuby KS, Gould RA, et al.: An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 2001, 158:1989\u20131992.","journal-title":"Am J Psychiatry"},{"key":"78_CR40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1034\/j.1600-0447.2002.02255.x","volume":"106","author":"A Bakker","year":"2002","unstructured":"Bakker A, van Balkom AJ, Spinhoven P: SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand 2002, 106:163\u2013167.","journal-title":"Acta Psychiatr Scand"},{"key":"78_CR41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/da.1053","volume":"14","author":"BR Slaap","year":"2001","unstructured":"Slaap BR, Den Boer JA: The prediction of nonresponse to pharmacotherapy in panic disorder: a review. Depress Anxiety 2001, 14:112\u2013122. This is an excellent review describing the predictors for nonresponse in short-term and long-term pharmacologic treatment in PD.","journal-title":"Depress Anxiety"},{"key":"78_CR42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0165-0327(03)00043-0","volume":"80","author":"P Berger","year":"2004","unstructured":"Berger P, Sachs G, Amering M, et al.: Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder. J Affect Disord 2004, 80:75\u201378.","journal-title":"J Affect Disord"},{"key":"78_CR43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0022-3956(02)00010-9","volume":"36","author":"MH Pollack","year":"2002","unstructured":"Pollack MH, Rapaport MH, Fayyad R, et al.: Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder. J Psychiatr Res 2002, 36:229\u2013236.","journal-title":"J Psychiatr Res"},{"key":"78_CR44","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4088\/JCP.v64n0404","volume":"64","author":"PP Roy-Byrne","year":"2003","unstructured":"Roy-Byrne PP, Russo J, Cowley DS, et al.: Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. J Clin Psychiatry 2003, 64:383\u2013389.","journal-title":"J Clin Psychiatry"},{"key":"78_CR45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0165-0327(94)00070-P","volume":"33","author":"BR Slaap","year":"1995","unstructured":"Slaap BR, van Vliet IM, Westenberg HG, et al.: Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report). J Affect Disord 1995, 33:31\u201338.","journal-title":"J Affect Disord"},{"key":"78_CR46","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0165-0327(02)00312-9","volume":"78","author":"T Overbeek","year":"2004","unstructured":"Overbeek T, Buchold H, Schruers K, et al.: Blood-injury related phobic avoidance as predictor of nonresponse to pharmacotherapy in panic disorder with agoraphobia. J Affect Disord 2004, 78:227\u2013233.","journal-title":"J Affect Disord"},{"key":"78_CR47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/da.10087","volume":"17","author":"JM Gorman","year":"2003","unstructured":"Gorman JM, Martinez JM, Goetz R, et al.: The effect of pharmacotherapist characteristics on treatment outcome in panic disorder. Depress Anxiety 2003, 17:88\u201393.","journal-title":"Depress Anxiety"},{"key":"78_CR48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00004850-200203000-00005","volume":"17","author":"BR Slaap","year":"2002","unstructured":"Slaap BR, Boshuisen ML, Van Roon AM, et al.: Heart rate variability as predictor of nonresponse to mirtazapine in panic disorder: A preliminary study. Int Clin Psychopharmacol 2002, 17:69\u201374.","journal-title":"Int Clin Psychopharmacol"},{"key":"78_CR49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/070674370304800604","volume":"48","author":"B Baker","year":"2003","unstructured":"Baker B, Khaykin Y, Devins G, et al.: Correlates of therapeutic response in panic disorder presenting with palpitations: heart rate variability, sleep, and placebo effect. Can J Psychiatry 2003, 48:381\u2013387.","journal-title":"Can J Psychiatry"},{"key":"78_CR50","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0165-1781(02)00222-6","volume":"112","author":"AM Valenca","year":"2002","unstructured":"Valenca AM, Nardi AE, Nascimento I, et al.: Early carbon dioxide challenge test may predict clinical response in panic disorder. Psychiatry Res 2002, 112:269\u2013272.","journal-title":"Psychiatry Res"},{"key":"78_CR51","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1590\/S0004-282X2002000300003","volume":"60","author":"AM Valenca","year":"2002","unstructured":"Valenca AM, Nardi AE, Nascimento I, et al.: Carbon dioxide test as an additional clinical measure of treatment response in panic disorder. Arq Neuropsiquiatr 2002, 60:358\u2013361.","journal-title":"Arq Neuropsiquiatr"},{"key":"78_CR52","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jpsychires.2004.01.001","volume":"38","author":"JM Woo","year":"2004","unstructured":"Woo JM, Yoon KS, Choi YH, et al.: The association between panic disorder and the L\/L genotype of catechol-O-methyltransferase. J Psychiatr Res 2004, 38:365\u2013370.","journal-title":"J Psychiatr Res"},{"key":"78_CR53","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1176\/appi.ajp.159.10.1785","volume":"159","author":"JM Woo","year":"2002","unstructured":"Woo JM, Yoon KS, Yu BH: Catechol O-methyltransferase genetic polymorphism in panic disorder. Am J Psychiatry 2002, 159:1785\u20131787.","journal-title":"Am J Psychiatry"},{"key":"78_CR54","first-page":"517","volume":"55","author":"BA Kolk van der","year":"1994","unstructured":"van der Kolk BA, Dreyfuss D, Michaels M, et al.: Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994, 55:517\u2013522.","journal-title":"J Clin Psychiatry"},{"key":"78_CR55","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4088\/JCP.v63n0305","volume":"63","author":"F Martenyi","year":"2002","unstructured":"Martenyi F, Brown EB, Zhang H, et al.: Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry 2002, 63:199\u2013206.","journal-title":"J Clin Psychiatry"},{"key":"78_CR56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/10401230009147096","volume":"12","author":"MA Hertzberg","year":"2000","unstructured":"Hertzberg MA, Feldman ME, Beckham JC, et al.: Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Ann Clin Psychiatry 2000, 12:101\u2013105.","journal-title":"Ann Clin Psychiatry"},{"key":"78_CR57","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/00004714-200204000-00013","volume":"22","author":"J Zohar","year":"2002","unstructured":"Zohar J, Amital D, Miodownik C, et al.: Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol 2002, 22:190\u2013195.","journal-title":"J Clin Psychopharmacol"},{"key":"78_CR58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00004850-199903000-00001","volume":"14","author":"R Hidalgo","year":"1999","unstructured":"Hidalgo R, Hertzberg MA, Mellman T, et al.: Nefazodone in post-traumatic stress disorder: results from six open-label trials. Int Clin Psychopharmacol 1999, 14:61\u201368.","journal-title":"Int Clin Psychopharmacol"},{"key":"78_CR59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-244X-4-24","volume":"4","author":"JL Berlant","year":"2004","unstructured":"Berlant JL: Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 2004, 4:24.","journal-title":"BMC Psychiatry"},{"key":"78_CR60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jpsychires.2004.01.005","volume":"38","author":"J Davidson","year":"2004","unstructured":"Davidson J, Landerman LR, Clary CM: Improvement of anger at one week predicts the effects of sertraline and placebo in PTSD. J Psychiatr Res 2004, 38:497\u2013502.","journal-title":"J Psychiatr Res"},{"key":"78_CR61","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-0327(03)00047-8","volume":"80","author":"S Seedat","year":"2004","unstructured":"Seedat S, Warwick J, van H, et al.: Single photon emission computed tomography in posttraumatic stress disorder before and after treatment with a selective serotonin reuptake inhibitor. J Affect Disord 2004, 80:45\u201353.","journal-title":"J Affect Disord"},{"key":"78_CR62","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1196\/annals.1314.012","volume":"1032","author":"JD Bremner","year":"2004","unstructured":"Bremner JD, Vermetten E: Neuroanotomical changes associated with pharmacotherapy in posttraumatic stress disorder. Ann N Y Acad Sci 2004, 1032:154\u2013157.","journal-title":"Ann N Y Acad Sci"},{"key":"78_CR63","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0924-977X(02)00152-9","volume":"13","author":"BR Lawford","year":"2003","unstructured":"Lawford BR, Young RM, Noble EP, et al.: D2 dopamine receptor gene polymorphism: Paroxetine and social functioning in posttraumatic stress disorder. Eur Neuropsychopharmacol 2003, 13:313\u2013320.","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-005-0078-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-005-0078-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-005-0078-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T18:54:38Z","timestamp":1707936878000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-005-0078-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["78"],"URL":"https:\/\/doi.org\/10.1007\/s11920-005-0078-4","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}